No institutional re-rating of psychedelic biotech before a concrete 2027 FDA or Phase 3 catalyst.

Large institutional investors — think pension funds and big asset managers — are not going to significantly increase their bets on psychedelic drug companies until something concrete happens, like an FDA approval or strong results from a late-stage clinical trial. The feel-good headlines and political momentum around psychedelics are already baked into stock prices, so investors are waiting for real proof before moving more money in.

Narrative is priced in; today produced no de-risking event. Institutions wait for readouts, not veteran bills.